Insulin-loaded biodegradable PLGA microcapsules: initial burst release controlled by hydrophilic additives.
We investigated the controlled release of human insulin at an initial stage from poly(DL-lactic-co-glycolic acid) (PLGA, M(w) 6600) spherical matrices. PLGA microcapsules were prepared by the novel solvent evaporation multiple emulsion process. When the crystalline insulin was dispersed in dichloromethane as solid-in-oil (S/O) dispersion, it was found that most of insulin molecules were inlaid on the surface of PLGA microcapsules. Consequently, insulin-loaded PLGA microcapsules exhibited marked rapid release of insulin within several hours in both in vivo and in vitro experiments. On the other hand, the addition of glycerol or water in the primary dichloromethane dispersion results in drastically suppressed initial release. It was found by SEM observation that water- or glycerol-in-oil (W/O or G/O) type mini-emulsion droplets with a mean diameter of 300-500 nm were formed in this primary solution. This phenomenon can be theoretically presumed to occur because insulin and PLGA molecules, having amphiphilic properties, converge on the interface between the hydrophilic additive and dichloromethane. Hence, insulin molecules heterogeneously located in the inside of PLGA microcapsules, not on the surface, would be gradually released with PLGA hydrolytic decomposition. As an additional effect of glycerol, the initial burst was further suppressed due to the decrease of the glass transition temperature of PLGA from 42.5 to 36.7 degrees C. Since the annealing of PLGA molecules took place at around 37 degrees C, the porous structure of microspheres immediately disappeared after immersion in PBS or subcutaneous administration. The insulin diffusion through the water-filled pores would be effectively prevented. The strict controlled initial release of insulin from the PLGA microsphere suggested the possibility of utilization in insulin therapy for type I diabetic patients who need construction of a basal insulin profile.
Yamaguchi
Y
Y
School of Medicine, Institute of Medical Science, St. Marianna University, Sugao 2-16-1 Miyamae-ku, Kawasaki-shi, Kanagawa-ken, Japan. yyamaguc@marianna-u.ac.jp
Takenaga
M
M
Kitagawa
A
A
Ogawa
Y
Y
Mizushima
Y
Y
Igarashi
R
R
D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry* / Q000493:pharmacokinetics; D001786:Blood Glucose / Q000032:analysis; D002214:Capsules; D018360:Crystallography, X-Ray; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000493:pharmacokinetics; D003921:Diabetes Mellitus, Experimental / Q000097:blood; D004055:Differential Thermal Analysis; D004655:Emulsions; D006801:Humans; D007328:Insulin / Q000737:chemistry* / Q000493:pharmacokinetics; D019344:Lactic Acid / Q000737:chemistry* / Q000493:pharmacokinetics; D008297:Male; D008855:Microscopy, Electron, Scanning; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry* / Q000493:pharmacokinetics; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry* / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D013499:Surface Properties; D013997:Time Factors
D001672:Biocompatible Materials; D001786:Blood Glucose; D002214:Capsules; D003692:Delayed-Action Preparations; D004655:Emulsions; D007328:Insulin; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid